Oliver M. Russell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oliver M. Russell has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Douglass M. Turnbull
Mitochondrial Research Group, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
4 shared publications Robert N. Lightowlers
Wellcome Centre for Mitochondrial Research, Institutes of Neuroscience and Cellular and Molecular Bioscience, Newcastle University Medical School, Newcastle University, Newcastle upon Tyne, UK
2 shared publications- Amy Elizabeth Vincent
Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
1 shared publication - Amy Katherine Reeve
Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK
1 shared publication Andreas W. Sailer
Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland
1 shared publication- Conor Lawless
Newcastle University
1 shared publication
Latest Publications
- Open Access
Strength training rescues mitochondrial dysfunction in skeletal muscle of patients with myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder, for which no cure exists. This study investigates the effects of 12-week strength training on mitochondrial oxidative phosphorylation in skeletal muscle in a cohort of DM1 patients (n=11, males) in comparison to untrained sex-matched healthy subjects. Immunofluorescence was used to assess protein levels of key respiratory chain subunits of complex I (CI) and complex IV (CIV), and markers of mitochondrial mass and cell membrane in individual myofibers sampled from biopsies. We classified each patient myofiber as having normal, low or high levels of CI and CIV and compared the proportions of affected fibers before and after exercise training. The significance of changes observed between pre- and post-exercise training within patients was estimated using a permutation test. At baseline, DM1 patients present with significantly decreased mitochondrial mass, and isolated or combined CI and CIV deficiency. After strength training, in most patients a significant increase in mitochondrial mass was observed, and all patients showed a significant increase in CI and/or CIV protein levels. Remarkably, 12-week strength training is sufficient to partially rescue mitochondrial dysfunction in DM1 patients, suggesting exercise as an inexpensive and accessible therapy option.
Open AccessStrength training rescues mitochondrial dysfunction in skeletal muscle of patients with myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder, for which no cure exists. This study investigates the effects of 12-week strength training on mitochondrial oxidative phosphorylation in skeletal muscle in a cohort of DM1 patients (n=11, males) in comparison to untrained sex-matched healthy subjects. Immunofluorescence was used to assess protein levels of key respiratory chain subunits of complex I (CI) and complex IV (CIV), and markers of mitochondrial mass and cell membrane in individual myofibers sampled from biopsies. We classified each patient myofiber as having normal, low or high levels of CI and CIV and compared the proportions of affected fibers before and after exercise training. The significance of changes observed between pre- and post-exercise training within patients was estimated using a permutation test. At baseline, DM1 patients present with significantly decreased mitochondrial mass, and isolated or combined CI and CIV deficiency. After strength training, in most patients a significant increase in mitochondrial mass was observed, and all patients showed a significant increase in CI and/or CIV protein levels. Remarkably, 12-week strength training is sufficient to partially rescue mitochondrial dysfunction in DM1 patients, suggesting exercise as an inexpensive and accessible therapy option.
- Open Access
- 29 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-10
Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo
We generated induced pluripotent stem cells (iPSCs) from patient fibroblasts to yield cell lines containing varying degrees of heteroplasmy for a m.13514 A > G mtDNA point mutation (2 lines) and for a ~6 kb single, large scale mtDNA deletion (3 lines). Long term culture of the iPSCs containing a single, large-scale mtDNA deletion showed consistent increase in mtDNA deletion levels with time. Higher levels of mtDNA heteroplasmy correlated with increased respiratory deficiency. To determine what changes occurred in deletion level during differentiation, teratomas comprising all three embryonic germ layers were generated from low (20%) and intermediate heteroplasmy (55%) mtDNA deletion clones. Regardless of whether iPSCs harbouring low or intermediate mtDNA heteroplasmy were used, the final levels of heteroplasmy in all teratoma germ layers increased to a similar high level (>60%). Thus, during human stem cell division, cells not only tolerate high mtDNA deletion loads but seem to preferentially replicate deleted mtDNA genomes. This has implications for the involvement of mtDNA deletions in both disease and ageing.
- 29 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-10
Open AccessPreferential amplification of a human mitochondrial DNA deletion in vitro and in vivo
We generated induced pluripotent stem cells (iPSCs) from patient fibroblasts to yield cell lines containing varying degrees of heteroplasmy for a m.13514 A > G mtDNA point mutation (2 lines) and for a ~6 kb single, large scale mtDNA deletion (3 lines). Long term culture of the iPSCs containing a single, large-scale mtDNA deletion showed consistent increase in mtDNA deletion levels with time. Higher levels of mtDNA heteroplasmy correlated with increased respiratory deficiency. To determine what changes occurred in deletion level during differentiation, teratomas comprising all three embryonic germ layers were generated from low (20%) and intermediate heteroplasmy (55%) mtDNA deletion clones. Regardless of whether iPSCs harbouring low or intermediate mtDNA heteroplasmy were used, the final levels of heteroplasmy in all teratoma germ layers increased to a similar high level (>60%). Thus, during human stem cell division, cells not only tolerate high mtDNA deletion loads but seem to preferentially replicate deleted mtDNA genomes. This has implications for the involvement of mtDNA deletions in both disease and ageing.
- Open Access
- 1 April 2016
- Published by Elsevier in Molecular Cell
- Vol. 62 (1) , 5-6
Applying the Airbrakes: Treating Mitochondrial Disease with Hypoxia
- 1 April 2016
- Published by Elsevier in Molecular Cell
- Vol. 62 (1) , 5-6
Open AccessApplying the Airbrakes: Treating Mitochondrial Disease with Hypoxia
- Open Access
- 20 November 2015
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 116 (1) , 5-18
Potential compounds for the treatment of mitochondrial disease
Mitochondrial diseases are a group of heterogeneous disorders for which no curative therapy is currently available. Several drugs are currently being pursued as candidates to correct the underlying biochemistry that causes mitochondrial dysfunction. A systematic review of pharmacological therapeutics tested using in vitro, in vivo models and clinical trials. Results presented from database searches undertaken to ascertain compounds currently being pioneered to treat mitochondrial disease. Previous clinical research has been hindered by poorly designed trials that have shown some evidence in enhancing mitochondrial function but without significant results. Several compounds under investigation display poor pharmacokinetic profiles or numerous off target effects. Drug development teams should continue to screen existing and novel compound libraries for therapeutics that can enhance mitochondrial function. Therapies for mitochondrial disorders could hold potential cures for a myriad of other ailments associated with mitochondrial dysfunction such as neurodegenerative diseases.
- 20 November 2015
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 116 (1) , 5-18
Open AccessPotential compounds for the treatment of mitochondrial disease
Mitochondrial diseases are a group of heterogeneous disorders for which no curative therapy is currently available. Several drugs are currently being pursued as candidates to correct the underlying biochemistry that causes mitochondrial dysfunction. A systematic review of pharmacological therapeutics tested using in vitro, in vivo models and clinical trials. Results presented from database searches undertaken to ascertain compounds currently being pioneered to treat mitochondrial disease. Previous clinical research has been hindered by poorly designed trials that have shown some evidence in enhancing mitochondrial function but without significant results. Several compounds under investigation display poor pharmacokinetic profiles or numerous off target effects. Drug development teams should continue to screen existing and novel compound libraries for therapeutics that can enhance mitochondrial function. Therapies for mitochondrial disorders could hold potential cures for a myriad of other ailments associated with mitochondrial dysfunction such as neurodegenerative diseases.
- Open Access
- 1 July 2014
- Published by Elsevier in Experimental Cell Research
- Vol. 325 (1) , 38-43
Mitochondrial DNA disease—molecular insights and potential routes to a cure
- 1 July 2014
- Published by Elsevier in Experimental Cell Research
- Vol. 325 (1) , 38-43
Open AccessMitochondrial DNA disease—molecular insights and potential routes to a cure